Chronic Kidney Disease (End Stage Renal Disease)
Conditions
Interventions
Dialysis therapy using VPS-HA for a week. Hollow-fiber dialyzers will be changed from VPS-HA to VPS-VA. Dialysis therapy using VPS-VA for two weeks.
Sponsors
Toho Hospital, Sanshikai Medical Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients on stable maintenance dialysis therapy using VPS-HA at least three months. 2)Patients with capable of dialysis therapy using the type IIa hollow-fiber dialyzer. 3)Patients with capable of obtaining blood flow rate >= 200 mL/min. 4)Patients who are capable to participate in the study as outpatients. 5)Patients capable of understanding the informed consent form. 6)Patients >= 20 years and <85 years of age at the time of informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients requiring another blood purification therapy such as peritoneal dialysis other than hemodiafiltration within this study period. 2)Patients with a medical history of anaphylaxis symptoms caused by polysulfone or polyvinylpyrrolidone (PVP). 3)Patients with a medical history of anaphylaxis symptoms caused by vitamin E-coated membrane. 4)Patients in the opinion of the principal investigator to disqualify from participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Beta 2-microglobulin clearance | — |
Countries
Japan
Contacts
Public ContactMasaki Matsumura
Toho Hospital, Sanshikai Medical Corporation Kidney dialysis center
Outcome results
None listed